Current treatment practice and outcomes. Report of the hyponatremia registry

Kidney International

Volumn 88, Issue 1, 2015, Pages 167-177

  Greenberg, Arthur ^a   Verbalis, Joseph G ^b   Amin, Alpesh N ^c   Burst, Volker R ^d   Chiodo Iii, Joseph A ^e   Chiong, Jun R ^f   Dasta, Joseph F ^g   Friend, Keith E ^e   Hauptman, Paul J ^h   Peri, Alessandro ⁱ   Sigal, Samuel H ^j  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^e OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^f LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^h SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF FLORENCE   (Italy)

^j NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Acid base and electrolytes; Geriatric nephrology; Vasopressin; Water and volume homeostasis

Indexed keywords

DEMECLOCYCLINE; DESMOPRESSIN; HYDROCORTISONE; ISOTONIC SOLUTION; LOOP DIURETIC AGENT; SODIUM; SODIUM CHLORIDE; TOLVAPTAN; UREA; BENZAZEPINE DERIVATIVE; VASOPRESSIN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES INSIPIDUS; DISEASE SEVERITY; EUROPEAN UNION; FEMALE; HOSPITAL COST; HOSPITAL READMISSION; HUMAN; HYPERVOLEMIA; HYPONATREMIA; HYPOVOLEMIA; INAPPROPRIATE VASOPRESSIN SECRETION; LENGTH OF STAY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REGISTER; SENSITIVITY ANALYSIS; SERUM OSMOLALITY; SODIUM BLOOD LEVEL; UNITED STATES; URINE OSMOLALITY; BLOOD; FLUID THERAPY; MIDDLE AGED; OSMOLARITY; TREATMENT OUTCOME;

AGED; ANTIDIURETIC HORMONE RECEPTOR ANTAGONISTS; BENZAZEPINES; FEMALE; FLUID THERAPY; HUMANS; HYPONATREMIA; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; REGISTRIES; SALINE SOLUTION, HYPERTONIC; SODIUM; TREATMENT OUTCOME;

EID: 84934436877     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.4     Document Type: Article

References (36)

1. Hawkins RC. Age and gender as risk factors for hyponatremia and hypernatremia. Clin Chim Acta 2003; 337: 169-172.
2. Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med 2006; 119: S30-S35.
3. Gheorghiade M, Abraham WT, Albert NM et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007; 28: 980-988.
4. Ruf AE, Kremers WK, Chavez LL et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11: 336-343.
5. Kim WR, Biggins SW, Kremers WK et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359: 1018-1026.
6. Wald R, Jaber BL, Price LL et al. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med 2010; 170: 294-302.
7. Corona G, Giuliani C, Parenti G et al. Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis. PLoS One 2013; 8: e80451.
8. Shea AM, Hammill BG, Curtis LH et al. Medical costs of abnormal serum sodium levels. J Am Soc Nephrol 2008; 19: 764-770.
9. Amin A, Deitelzweig S, Christian R et al. Evaluation of incremental healthcare resource burden and readmission rates associated with hospitalized hyponatremic patients in the US. J HospMed 2012; 7: 634-639.
10. Renneboog B, Musch W, Vandemergel X et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006; 119: 71-78.
11. Kinsella S, Moran S, Sullivan MO et al. Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clini J Am Soc Nephrol 2010; 5: 275-280.
12. Hoorn EJ, Rivadeneira F, van Meurs JB et al. Mild hyponatremia as a risk factor for fractures: the Rotterdam Study. J Bone Miner Res 2011; 26: 1822-1828.
13. Verbalis JG, Barsony J, Sugimura Y et al. Hyponatremia-induced osteoporosis. J Bone Miner Res 2010; 25: 554-563.
14. Hoorn EJ, Zietse R. Hyponatremia and mortality: moving beyond associations. Am J Kidney Dis 2013; 62: 139-149.
15. Fraser CL, Arieff AI. Epidemiology, pathophysiology, and management of hyponatremic encephalopathy. Am J Med 1997; 102: 67-77.
16. Hauptman PJ, Burnett J, Gheorghiade M et al. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail 2013; 19: 390-397.
17. Rossi J, Bayram M, Udelson JE et al. Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care 2007; 9: 82-86.
18. Schrier RW, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112.
19. Hauptman PJ, Greenberg A, Verbalis JG et al. Design of a prospective, multinational registry to evaluate patients hospitalized with hyponatremia: the HN Registry. Open Access Journal of Clnical Trials 2013; 5: 93-100.
20. Verbalis JG, Goldsmith SR, Greenberg A et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med 2013; 126: S1-S42.
21. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342: 1581-1589.
22. Spasovski G, Vanholder R, Allolio B et al. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Nephrol Dial Transplant 2014; 29: i1-i39.
23. Schwartz WB, Bennett W, Curelop S et al. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957; 23: 529-542.
24. Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 1967; 42: 790-806.
25. Huda MS, Boyd A, Skagen K et al. Investigation and management of severe hyponatraemia in a hospital setting. Postgrad Med J 2006; 82: 216-219.
26. Clayton JA, Le Jeune IR, Hall IP. Severe hyponatraemia in medical in-patients: aetiology, assessment and outcome. QJM 2006; 99: 505-511.
27. Waikar SS, Mount DB, Curhan GC et al. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009; 122: 857-865.
28. Barsony J, Manigrasso MB, Xu Q et al. Chronic hyponatremia exacerbates multiple manifestations of senescence in male rats. Age (Dordr) 2013; 35: 271-288.
29. Movafagh S, Cleemann L, Morad M. Regulation of cardiac Ca2 channel by extracellular Na. Cell Calcium 2011; 49: 162-173.
30. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007; 356: 2064-2072.
31. Furst H, Hallows KR, Post J et al. The urine/plasma electrolyte ratio: a predictive guide to water restriction. Am J Med Sci 2000; 319: 240-244.
32. Verbalis JG, Adler S, Schrier RW et al. Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol 2011; 164: 725-732.
33. Malhotra I, Gopinath S, Janga KC et al. Unpredictable nature of tolvaptan in treatment of hypervolemic hyponatremia: case review on role of vaptans. Case Rep Endocrinol 2014; 2014: 807054.
34. Anderson RJ, Chung HM, Kluge R et al. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985; 102: 164-168.
35. Soupart A, Coffernils M, Couturier B et al. Efficacy and Tolerance of urea compared with vaptans for long-term treatment of patients with SIADH. Clin J Am Soc Nephrol 2012; 7: 742-747.
36. Fenske W, Stork S, Koschker AC et al. Value of fractional uric acid excretion in differential diagnosis of hyponatremic patients on diuretics. J Clinical Endocrinol Metab 2008; 93: 2991-2997.